These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21278561)

  • 1. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver.
    Kennedy A; Coldwell D; Sangro B; Wasan H; Salem R
    Am J Clin Oncol; 2012 Aug; 35(4):393-8. PubMed ID: 21278561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis.
    Devcic Z; Rosenberg J; Braat AJ; Techasith T; Banerjee A; Sze DY; Lam MG
    J Nucl Med; 2014 Sep; 55(9):1404-10. PubMed ID: 25012459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies.
    Kennedy AS; Salem R
    Cancer J; 2010; 16(2):163-75. PubMed ID: 20404614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
    Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
    J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers.
    Coldwell D; Sangro B; Salem R; Wasan H; Kennedy A
    Am J Clin Oncol; 2012 Apr; 35(2):167-77. PubMed ID: 21127414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
    Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
    Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for unresectable neuroendocrine liver metastases.
    John BJ; Davidson BR
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):357-69. PubMed ID: 22646257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization.
    Murthy R; Kamat P; Nunez R; Madoff DC; Gupta S; Salem R; Yao JC
    J Vasc Interv Radiol; 2008 Jan; 19(1):145-51. PubMed ID: 18192482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.
    Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Minor DR; Sze DY
    J Vasc Interv Radiol; 2012 Mar; 23(3):323-30.e1. PubMed ID: 22277275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic neuroendocrine hepatic tumors: resection improves survival.
    Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
    Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
    Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S
    Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
    Jia Z; Wang W
    Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.
    Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R
    Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.